For & Against
What's Next
Guan Chong trades at RM 0.835 — roughly book value, ~8.8x trailing earnings, ~40% below the 18-year median P/E and 42% below the RM 1.44 twelve-month fair value. The setup over the next six months is unusually well-dated for a Malaysian mid-cap: one annual report release, one AGM, two quarterly prints, and a visibly moving cocoa tape (Ivory Coast farmgate −57% in Feb 2026, Ghana −28.6% earlier). The market is positioned for the wrong variable — it is still watching the FY2024 leverage peak (net debt/EBITDA 5.0x) instead of the FY2025 deleveraging (RM 914M debt repaid, RM 884M FCF). The test dates below will force a reprice.
What the market is watching most closely: net debt / EBITDA and operating cash flow / net income each quarter. Everything else — Transcao, ESG/EUDR, industrial chocolate mix — is background next to whether deleveraging is structural. The Street target of RM 1.53 is doing the talking; the tension is whether it materialises before or after the Q2 FY2026 confirmation print.
For / Against / My View
For
The FY2025 cash reversal is already printed. Net income fell 47%, but operating cash flow swung from −RM 1,676M to +RM 1,172M and RM 914M of debt was retired — the single biggest deleveraging year in company history, without a rights issue. Per Quant, debt/equity fell from 2.02x to 1.43x in twelve months. The market is still pricing the FY2024 leverage peak; the balance sheet no longer looks like the one that spooked holders through 2024-25.
The cheapest trailing multiples in seven years, sitting on real book value. 8.8x P/E vs 18-year median of 10.9x and 5-year median of 17.7x; EV/EBITDA 8.1x vs 10.9x median; price-to-book 0.88x. Per Warren, shares trade below tangible book. Book value has compounded ~16% annually for a decade. Quant's bear case (RM 0.55) requires leverage to re-expand and the through-cycle EPS thesis to break — not just valuation to stay flat.
Insider and institutional buying into the drawdown. CEO Tay Hoe Lian bought 200,000 shares at RM 0.71 on 6 April 2026 — a buy, not a sale, at a 57% drawdown from the 2025 peak. KWAP (Malaysian state pension) grew its position 734% in 2025; Norges Bank added 19M shares. Institutional sponsorship strengthened through the worst year. The controlling family's paper loss dwarfs the entire executive pay bill — genuine downside alignment per Sherlock.
Cocoa price normalisation is a direct 2026 tailwind. Ivory Coast cut farmgate cocoa prices ~57% in Feb 2026; Ghana cut 28.6% earlier. For a grinder whose working capital inflates with bean prices, reversion means inventory releases cash and spread economics recover as legacy hedges roll off. This is the mirror image of the FY2023-24 squeeze — and FY2025 already showed the mechanic working in reverse.
A dated, binary re-rating catalyst inside ten weeks. Q1 FY2026 earnings (~1 June 2026) is the first quarter without the FY2025 realised-hedging-loss overhang. If CFO/NI stays above 1.0x and net debt / EBITDA prints below 4x, the consensus RM 1.53 target becomes the gravitational centre. A dated re-rating window, not a vague "eventually."
Against
Earnings are still late-cycle, not mid-cycle. Warren is explicit: through-cycle EPS is probably RM 0.08-0.10, not the FY2024 print of RM 0.157. Quant's base case (RM 1.25) uses normalised EPS of RM 0.10 at 11x — fairly valued, not cheap. The "40% discount to median P/E" only works if you trust the trailing number. Five of the last six years of FCF have been negative; cumulative FCF over FY2021-FY2024 was −RM 4.1B on +RM 929M cumulative net income. The numbers Warren and Quant agree on are not the numbers on the earnings page.
Net debt / EBITDA is still ~4.9x after the best deleveraging year on record. Even with RM 914M repaid, leverage sits well above the 2x bar commodity processors are held to. Interest expense was RM 337M in FY2025 — 53% of operating income. Per Sherlock, ~14% of the promoter stake sits in pledged-securities accounts at RHB and AmBank. A second leg down in spreads before the debt pay-down completes — high beans plus weak butter ratio — is the thesis-breaker. It is not valuation and it is not governance; it is a single quarter of working capital going the wrong way.
The 2014 template is live and un-narrated. Historian's clearest finding: FY2014, the only outright net loss in the 18-year dataset, was caused by the same mechanism now unwinding — cocoa butter ratios reversed against the book. Management never explicitly framed that episode; the FY2024 "record profit" has been recast as "ability to adapt" rather than a cocoa-price windfall. Historian's 5.5/10 credibility score is precisely because wins are structural and losses are external. If Q1 FY2026 disappoints, the Street will re-read FY2024 as the cyclical peak it was — and the trailing P/E denominator collapses with it.
No moat, no pricing power, no diversification away from the bean. Per Warren, scale does not buy margin in cocoa grinding — Barry Callebaut is 4x the size and earns the same 4% operating margin. Through-cycle op margin is ~5%, through-cycle ROE 7-8%. SCHOKINAG and UK Glemsford have not produced the Barry Callebaut-style 8%+ industrial-chocolate margins that would de-commoditise the story. Until that shift is in the numbers, the stock is a commodity proxy with no structural reason to re-rate above peer median.
Governance is founder-operator; minorities are downstream. Sherlock's C+ grade is honest. Pay jumped 58% into the cocoa peak with no disclosed LTIP formula or clawback; the RC chair and Board Chair share a prior law firm; the FY2025 remuneration disclosure is the first real pay-for-performance test and it lands in April/May. RRPT with Enrich Mix doubled YoY. Three executives in their 60s, no disclosed succession. Dividends were 11% of net income even in a record year — capital allocation favours capex and working capital, not payout.
My View
The Against side edges the For side, but only just — and the edge is narrower than the 40% discount to median P/E suggests. The real tension across the four specialists is that Warren's commodity-processor framing and Quant's balance-sheet math both argue the trailing earnings number is the wrong denominator, while Historian's narrative track and Sherlock's ownership read both say the family and the Street are positioned for the same reversal trade (CEO buying, KWAP and Norges building, consensus target ~RM 1.53). The For case depends entirely on a valuation re-rating from a trailing number that has failed to sustain four of the last six years; the Against case has a clean mechanism (leverage above 4x, hedges still bleeding, no structural margin fix) and a dated test six weeks out. The single data point that flips the view is Q1 FY2026 operating cash flow / net income above 1.0x with net debt / EBITDA printing under 4x — that converts "cocoa round-trip" from hope to arithmetic, and at that point the RM 1.25-1.50 base case has a clear runway. Absent that print, below-book on a late-cycle commodity processor is priced correctly, not mispriced.